Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma

[1]  H. Nagase,et al.  ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression , 2017, Medical Oncology.

[2]  D. Chung,et al.  Induced differentiation inhibits sphere formation in neuroblastoma. , 2016, Biochemical and biophysical research communications.

[3]  Wang-Tso Lee,et al.  Calreticulin Regulates VEGF-A in Neuroblastoma Cells , 2014, Molecular Neurobiology.

[4]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[5]  W. Shoji,et al.  NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas , 2014, PLoS genetics.

[6]  William A Weiss,et al.  Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.

[7]  Bandana Sharma,et al.  The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. , 2012, Cancer cell.

[8]  H. Juan,et al.  Calreticulin Mediates Nerve Growth Factor-Induced Neuronal Differentiation , 2012, Journal of Molecular Neuroscience.

[9]  P. Northcott,et al.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. , 2012, Cancer cell.

[10]  Rani E. George,et al.  Promising Therapeutic Targets in Neuroblastoma , 2012, Clinical Cancer Research.

[11]  D. Neuberg,et al.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.

[12]  J. Maris,et al.  PI3King on MYCN to improve neuroblastoma therapeutics. , 2012, Cancer cell.

[13]  K. Matthay,et al.  Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma , 2012, Science Translational Medicine.

[14]  A. Biankin,et al.  SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability , 2011, PLoS genetics.

[15]  F. Stossi,et al.  Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects , 2010, Oncogene.

[16]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[17]  H. Juan,et al.  Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma , 2010, Clinical Cancer Research.

[18]  J. Lunec,et al.  MYCN oncoprotein targets and their therapeutic potential. , 2010, Cancer letters.

[19]  Shinya Yamanaka,et al.  Promotion of direct reprogramming by transformation-deficient Myc , 2010, Proceedings of the National Academy of Sciences.

[20]  E. Prochownik,et al.  Therapeutic Targeting of Myc. , 2010, Genes & cancer.

[21]  F. Westermann,et al.  Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. , 2010, Cancer research.

[22]  W. Weiss,et al.  Myc proteins as therapeutic targets , 2010, Oncogene.

[23]  Nunzio Iraci,et al.  p53 is a direct transcriptional target of MYCN in neuroblastoma. , 2010, Cancer research.

[24]  K. Matthay,et al.  Neuroblastoma: Biology and staging , 2009, Current oncology reports.

[25]  M. Danks,et al.  New therapeutic targets for the treatment of high‐risk neuroblastoma , 2009, Journal of cellular biochemistry.

[26]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[27]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[28]  D. Chung,et al.  MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. , 2006, Biochemical and biophysical research communications.

[29]  H. Ding,et al.  Bmi-1 Regulates the Differentiation and Clonogenic Self-renewal of I-type Neuroblastoma Cells in a Concentration-dependent Manner* , 2006, Journal of Biological Chemistry.

[30]  L. Doering,et al.  Neural Stem Cell Culture: Neurosphere generation, microscopical analysis and cryopreservation , 2006 .

[31]  P. Brown,et al.  Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. , 2006, The Biochemical journal.

[32]  K. Nowak,et al.  BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas , 2006, Nucleic acids research.

[33]  N. Kaiser,et al.  Calreticulin Destabilizes Glucose Transporter-1 mRNA in Vascular Endothelial and Smooth Muscle Cells Under High-Glucose Conditions , 2005, Circulation research.

[34]  William C Hahn,et al.  The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. , 2005, Developmental cell.

[35]  D. Lai,et al.  Calreticulin expression in neuroblastoma--a novel independent prognostic factor. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Miki Ohira,et al.  Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. , 2004, Cancer letters.

[37]  W. Lutz,et al.  E2F and Sp1/Sp3 Synergize but Are Not Sufficient to Activate the MYCN Gene in Neuroblastomas* , 2004, Journal of Biological Chemistry.

[38]  W. Weiss,et al.  Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. , 2003, Journal of the National Cancer Institute.

[39]  W. Lutz,et al.  E2F Proteins Regulate MYCN Expression in Neuroblastomas* , 2003, The Journal of Biological Chemistry.

[40]  A. Iavarone,et al.  Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins , 2000, Nature.

[41]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[42]  S. Dedhar,et al.  Ligand-specific, transient interaction between integrins and calreticulin during cell adhesion to extracellular matrix proteins is dependent upon phosphorylation/dephosphorylation events. , 1999, The Biochemical journal.

[43]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[44]  K. Kullander,et al.  Neurotrophins and their receptors in chicken neuronal development. , 1995, The International journal of developmental biology.

[45]  M. Shago,et al.  Inhibition of nuclear hormone receptor activity by calreticulin , 1994, Nature.

[46]  K. Burns,et al.  Modulation of gene expression by calreticulin binding to the glucocorticoid receptor , 1994, Nature.

[47]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[48]  J. H. Wright.  NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED , 1910, The Journal of experimental medicine.

[49]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.

[50]  F. Alt,et al.  Differential expression of myc family genes during murine development , 1986, Nature.